Table 3.

Treatment outcomes at D28

	Treatment outcome (No, %) [95 CI]
	Rural area (n = 62)	Urban area (n = 55)	Total (n = 117)
ETF	0 (0%) [0–6%]	0 (0%) [0–6%]	0 (0%) [0–3%]
LCF
- Recrudescence	9 (15%) [7–26%]	11 (20%) [10–33%]	20 (17%) [11–25%]
- New infection	5 (8%) [3–18%]	7 (13%) [5–24%]	12 (10%) [5–17%]
- No genotyping results	2 (3%) [0–11%]	2 (4%) [0–13%]	4 (3%) [1–9%]
LPF
- Recrudescence	14 (23%) [13–35%]	5 (9%) [3–20%]	19 (16%) [10–24%]
- New infection	17 (27%) [17–40%]	14 (25%) [15–39%]	31 (26%) [19–35%]
- No genotyping results	2 (3%) [0–11%]	1 (2%) [0–10%]	3 (3%) [1–7%]
ACPR	13 (21%) [12–33%]	15 (27%) [16–41%]	28 (24%) [17–33%]
ACPR (PCR-corrected)	35 (56%) [43–69%]	36 (65%) [51–78%]	71 (61%) [51–70%]